Keyword: Ionis Pharmaceuticals
AveXis is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) as it plays catch-up with Biogen and Ionis.
Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.
The gene silencing pioneer expects to complete the submission by the end of the year, setting it up to win approval in the U.S. in 2018.
Hal Barron replaces Patrick Vallance as GSK CSO, Biogen lured Merck exec to head global marketing and Celgene vet Pehl lands at Immunomedics.
Data presented by the RNAi pioneer Alnylam suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy.
The data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of challenging Biogen’s Spinraza.
The deal connects Ionis to the manufacturer of a blood collection device that could simplify mitigation of its drugs’ safety risks.
The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.
Akcea sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome to market in the U.S. next year.
Canadian investment group TRC Capital—well known for its min-tender offer strategy—has now set its sights on Ionis, and the biotech group is not happy.